Zevra Therapeutics Sets Q3 2026 Financial Results Conference Call

BOSTON, Oct. 20, 2026 /CourierPR/ -- Zevra Therapeutics, a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, will release its third-quarter 2026 financial results on Tuesday, November 3, 2026, via a news release after the market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. Interested parties can join the call by dialing (800) 274-8461 in the United States or +1 (203) 518-9814 internationally. The conference ID is ZVRAQ326.

A replay of the webcast will be available for 90 days starting at approximately 5:30 p.m. ET on the same day. The replay can be accessed on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com. This information is provided in accordance with the Private Securities Litigation Reform Act of 1995, and forward-looking statements are based on information currently available to Zevra and its current plans or expectations. These statements are subject to several known and unknown uncertainties, risks, and other important factors that may cause Zevra’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These factors are detailed in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values, patient centricity, integrity, accountability, innovation, and courage, which guide its efforts to deliver long-term value.